Immuron Ltd (ASX:IMC) Shares Jump as Travelan Sales and FY27 Plans Draw Attention

Sonal Goyal

07 October 2026 06:49 PM AEDT

Immuron Ltd (ASX:IMC) Shares Jump as Travelan Sales and FY27 Plans Draw Attention

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Immuron (ASX:IMC) traded at AUD 0.045, up 18.42% on October 7, 2026.
FY26 global sales revenue was reported at AUD 7.7 million, up 6%.
Australian sales revenue reached AUD 5.8 million, while US sales revenue was AUD 1.8 million.
Immuron reported FY26 cash of AUD 9.0 million and a net loss of AUD 3.8 million.

Immuron Ltd is a biotechnology company focused on orally delivered products and therapeutic programs targeting gastrointestinal conditions. Its commercial portfolio includes Travelan, a product used in travel-health settings, while development programs include IMM-529. Immuron was one of the sharper gainers on October 7, 2026. In trading today, Immuron (ASX:IMC) was quoted at AUD 0.045, up 18.42% at the time this article was prepared. The price movement is notable for the session, while the company's underlying position continues to be assessed through product sales, clinical development and cash management.

Company Business

Immuron's commercial business is centred on products for gastrointestinal health, with Travelan forming the main revenue-generating product. Sales are generated in Australia and the United States, giving the company exposure to travel-related consumer demand and pharmacy channels. Alongside commercial sales, Immuron is advancing clinical assets, including IMM-529. This creates a mixed business model in which near-term revenue comes from established products while expenditure is also directed toward clinical and regulatory development. Geographic expansion and portfolio development are therefore important parts of the operating strategy.

Recent Development

Immuron's FY26 results presentation, released in late August 2026, reported global sales revenue of AUD 7.7 million, up 6%. Australian sales revenue increased to AUD 5.8 million, while US sales revenue was AUD 1.8 million. The company also highlighted completion of a Travelan clinical study involving 851 participants, FDA approval of the investigational new drug application for IMM-529 and a new US Department of Defense subaward. Management also outlined a strategic reset aimed at improving profitability and reducing cash burn while continuing commercial and clinical work.

Financial Performance and Sector Context

FY26 gross profit margin was reported at 64.5%. The company recorded a net loss of AUD 3.8 million, an improvement of AUD 1.4 million from the prior period, and finished the year with AUD 9.0 million in cash. Immuron indicated that its cash resources were expected to support operations through FY27 and into FY28, subject to actual spending and commercial performance. For the travel-health segment, sales can be influenced by travel activity, product awareness, pharmacy distribution and geographic expansion. For the development portfolio, clinical timelines and regulatory outcomes remain separate drivers of expenditure and value creation.

Risks to Consider

Key risks include variability in Travelan demand, the cost and timing of clinical programs, regulatory uncertainty and continued cash use while development work proceeds. The company is also exposed to the execution risk involved in expanding sales outside Australia. Clinical programs can require additional studies, regulatory submissions or partnering activity before they contribute materially to revenue.

What to Watch Next

Investors may watch FY27 Travelan sales, the pace of US and other geographic expansion, progress on IMM-529 partnering and clinical milestones, and evidence that operating losses and cash burn continue to narrow. Updates on product launches and portfolio expansion will also help indicate how the commercial and development sides of the business are progressing.

Key Insights

Immuron's FY26 results showed higher global sales revenue and a smaller net loss, while cash remained available to fund current priorities. The company's share price rose sharply on October 7, 2026, but future performance will depend on commercial execution in Travelan, progress across the clinical portfolio and continued control of expenditure. Those are the main factors to monitor as FY27 develops.

FAQs

Q:What was Immuron's share price on October 7, 2026?

A:IMC was trading at AUD 0.045, up 18.42% during the session at the time of writing.

Q:What is Immuron's main commercial product?

A:Travelan is the company's principal commercial product and is sold in travel-health markets.

Q:What revenue did Immuron report for FY26?

A:Global sales revenue was AUD 7.7 million, including AUD 5.8 million from Australia and AUD 1.8 million from the United States.

Q:Was Immuron profitable in FY26?

A:No. The company reported a net loss of AUD 3.8 million.

Q:What should investors monitor next?

A:Travelan sales, geographic expansion, IMM-529 progress, partnering activity and cash burn are key areas to follow.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.